These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28072862)

  • 21. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors affecting the efficacy and safety of phosphodiesterase 5 inhibitor and placebo in treatment for lower urinary tract symptoms: meta-analysis and meta-regression.
    Sun HY; Lee B; Kim JH
    Int Urol Nephrol; 2018 Jan; 50(1):35-47. PubMed ID: 29129027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH].
    Xiao H; Li HZ; Yang Y; Huang ZM; Li YQ; Zhao XF
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1590-3. PubMed ID: 17803845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis.
    Blake-James BT; Rashidian A; Ikeda Y; Emberton M
    BJU Int; 2007 Jan; 99(1):85-96. PubMed ID: 17026588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Martinelli E
    Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis.
    Kallidonis P; Adamou C; Kotsiris D; Ntasiotis P; Verze P; Athanasopoulos A;
    Eur Urol Focus; 2020 May; 6(3):537-558. PubMed ID: 31133414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
    Salah Azab S; Elsheikh MG
    Aging Male; 2015 Jun; 18(2):89-92. PubMed ID: 25295872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study.
    Bang WJ; Oh CY; Yoo C; Cho JS; Yang DY; Lee DH; Lee SH; Chung BH
    Int J Impot Res; 2013; 25(4):149-54. PubMed ID: 23303333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gallegos PJ; Frazee LA
    Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term alpha-blockers and anticholinergic combination treatment for men with lower urinary tract symptoms in real-life practice.
    Bae WJ; Bae JH; Choi YS; Kim SJ; Cho HJ; Hong SH; Kim SW; Hwang TK; Lee JY
    Int Urol Nephrol; 2012 Aug; 44(4):1077-84. PubMed ID: 22528586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
    Wang XH; Wang X; Shi MJ; Li S; Liu T; Zhang XH
    Asian J Androl; 2015; 17(6):1022-32. PubMed ID: 25994648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
    Sun Y; Peng B; Lei GL; Wei Q; Yang L
    Minerva Urol Nefrol; 2020 Feb; 72(1):13-21. PubMed ID: 31241273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: Study protocol for an assessor-blinded, randomized controlled clinical trial.
    Kim HB; Kim YI; Jeon JH; Kim E; Kim JY; Kwon O; Choi YE; Yang C; Han CH
    Medicine (Baltimore); 2020 Apr; 99(15):e19678. PubMed ID: 32282720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of anticholinergics in patients with benign prostatic hyperplasia.
    Athanasopoulos A; Mitropoulos D; Giannitsas K; Perimenis P
    Expert Opin Drug Saf; 2008 Jul; 7(4):473-9. PubMed ID: 18613810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.
    Zhang LT; Lee SW; Park K; Chung WS; Kim SW; Hyun JS; Moon DG; Yang SK; Ryu JK; Yang DY; Moon KH; Min KS; Park JK
    Clin Interv Aging; 2015; 10():277-86. PubMed ID: 25653511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
    Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
    Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
    Yoshida M; Sugiyama Y; Masunaga K; Maeda Y; Satoji Y; Nagata T; Inadome A
    Drugs Today (Barc); 2007 Jun; 43 Suppl B():1-7. PubMed ID: 17612712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical effectiveness and safety of combined therapy with an alpha-blocker and an anticholinergic drug for patients with benign prostatic hyperplasia].
    Xiao H; Li HZ; Huang ZM; Li YQ
    Zhonghua Wai Ke Za Zhi; 2010 Dec; 48(23):1771-3. PubMed ID: 21211380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis.
    Shim SR; Kim JH; Choi H; Lee WJ; Kim HJ; Bae MY; Hwang SD; Kim KH; Bae JH; Yoon SJ
    Curr Med Res Opin; 2015 Feb; 31(2):353-65. PubMed ID: 25350225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.